


Figure 1. (A) 50% responder rates and (B) seizure-freedom rates for patients receiving perampanel with concurrent use of levetiracetam, with prior use of levetiracetam before study entry, or with no use of levetiracetam, stratified by EIASM^a use (Full Analysis Set)



^aEIASMs are defined as carbamazepine, eslicarbazepine, oxcarbazepine, and phenytoin
EIASM, enzyme-inducing anti-seizure medication